|Bid||42.40 x 200000|
|Ask||43.80 x 200000|
|Day's range||42.40 - 43.20|
|52-week range||29.40 - 49.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
At this time, I'd like to welcome everyone to Eagle Pharmaceuticals first quarter 2022 financial results. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, investor relations for Eagle Pharmaceuticals.
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 3.32% and 5.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.